JP6726200B2 - 有機化合物 - Google Patents
有機化合物 Download PDFInfo
- Publication number
- JP6726200B2 JP6726200B2 JP2017549188A JP2017549188A JP6726200B2 JP 6726200 B2 JP6726200 B2 JP 6726200B2 JP 2017549188 A JP2017549188 A JP 2017549188A JP 2017549188 A JP2017549188 A JP 2017549188A JP 6726200 B2 JP6726200 B2 JP 6726200B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- salt form
- net
- free
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562135915P | 2015-03-20 | 2015-03-20 | |
| US62/135,915 | 2015-03-20 | ||
| PCT/US2016/023198 WO2016154027A1 (en) | 2015-03-20 | 2016-03-18 | Organic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508556A JP2018508556A (ja) | 2018-03-29 |
| JP2018508556A5 JP2018508556A5 (https=) | 2019-04-18 |
| JP6726200B2 true JP6726200B2 (ja) | 2020-07-22 |
Family
ID=56977765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549188A Active JP6726200B2 (ja) | 2015-03-20 | 2016-03-18 | 有機化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10188758B2 (https=) |
| EP (1) | EP3270920B1 (https=) |
| JP (1) | JP6726200B2 (https=) |
| KR (1) | KR20170129906A (https=) |
| CN (1) | CN107405339A (https=) |
| AU (1) | AU2016235483A1 (https=) |
| BR (1) | BR112017020135A2 (https=) |
| CA (1) | CA2978668A1 (https=) |
| ES (1) | ES2819833T3 (https=) |
| IL (1) | IL254320A0 (https=) |
| MX (1) | MX2017012022A (https=) |
| RU (1) | RU2017134796A (https=) |
| WO (1) | WO2016154027A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3339304A1 (en) | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Quinoline and isoquinoline derivatives for treating pain and pain related conditions |
| EP3339307A1 (en) * | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Nitrogen containing bicyclic derivatives for treating pain and pain related conditions |
| JP2022506378A (ja) * | 2018-11-02 | 2022-01-17 | エステベ ファーマシューティカルズ，ソシエダッド アノニマ | 疼痛及び疼痛に関連する状態を処置するための新規なテトラヒドロピリミドジアゼピン及びテトラヒドロピリドジアゼピン化合物 |
| EP3873901A1 (en) * | 2018-11-02 | 2021-09-08 | Esteve Pharmaceuticals, S.A. | New alcoxyaminopyridine derivatives for treating pain and pain related conditions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ313076A (en) * | 1995-07-24 | 1999-11-29 | Lilly Co Eli | Medicament containing duloxetine for treating hyperactivity and attention deficiency disorders |
| EP1587781A1 (en) * | 2002-11-05 | 2005-10-26 | Eli Lilly And Company | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| BRPI0510453A (pt) * | 2004-04-30 | 2007-10-30 | Warner Lambert Co | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central |
| WO2007010082A1 (en) * | 2005-07-15 | 2007-01-25 | Fermion Oy | Process for preparing a 3-aryloxy-3-arylpropylamine |
| EP2066630A1 (en) * | 2006-08-23 | 2009-06-10 | Pfizer Products Incorporated | Piperidine derivatives |
| ES2553891T3 (es) * | 2007-06-04 | 2015-12-14 | Intra-Cellular Therapies, Inc. | Derivados de piridina como moduladores NET/SERT |
| WO2010120910A1 (en) * | 2009-04-15 | 2010-10-21 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| US9352218B2 (en) | 2009-04-21 | 2016-05-31 | Nintendo Co., Ltd. | Game apparatus and computer-readable storage medium |
-
2016
- 2016-03-18 US US15/560,107 patent/US10188758B2/en active Active
- 2016-03-18 BR BR112017020135A patent/BR112017020135A2/pt not_active Application Discontinuation
- 2016-03-18 WO PCT/US2016/023198 patent/WO2016154027A1/en not_active Ceased
- 2016-03-18 CN CN201680014968.7A patent/CN107405339A/zh active Pending
- 2016-03-18 CA CA2978668A patent/CA2978668A1/en not_active Abandoned
- 2016-03-18 EP EP16769428.0A patent/EP3270920B1/en active Active
- 2016-03-18 KR KR1020177030305A patent/KR20170129906A/ko not_active Withdrawn
- 2016-03-18 MX MX2017012022A patent/MX2017012022A/es unknown
- 2016-03-18 ES ES16769428T patent/ES2819833T3/es active Active
- 2016-03-18 AU AU2016235483A patent/AU2016235483A1/en not_active Abandoned
- 2016-03-18 RU RU2017134796A patent/RU2017134796A/ru not_active Application Discontinuation
- 2016-03-18 JP JP2017549188A patent/JP6726200B2/ja active Active
-
2017
- 2017-09-04 IL IL254320A patent/IL254320A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2978668A1 (en) | 2016-09-29 |
| CN107405339A (zh) | 2017-11-28 |
| ES2819833T3 (es) | 2021-04-19 |
| US10188758B2 (en) | 2019-01-29 |
| BR112017020135A2 (pt) | 2018-05-29 |
| EP3270920B1 (en) | 2020-06-17 |
| RU2017134796A (ru) | 2019-04-04 |
| EP3270920A4 (en) | 2018-10-24 |
| JP2018508556A (ja) | 2018-03-29 |
| MX2017012022A (es) | 2018-01-30 |
| WO2016154027A1 (en) | 2016-09-29 |
| AU2016235483A1 (en) | 2017-10-12 |
| IL254320A0 (en) | 2017-11-30 |
| EP3270920A1 (en) | 2018-01-24 |
| KR20170129906A (ko) | 2017-11-27 |
| US20180099060A1 (en) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3346562B2 (ja) | Ｐｃｐレセプター・リガンドおよびそれらを含む薬剤 | |
| ES2329739T3 (es) | Analogos de cocaina. | |
| JP6968899B2 (ja) | 向精神薬およびその使用 | |
| EA011033B1 (ru) | 3-замещенные-2(арилалкил)-1-азабициклоалканы и способы их применения | |
| JP6726200B2 (ja) | 有機化合物 | |
| JP2020502195A (ja) | 疼痛および疼痛に関連する状態を処置するための窒素含有二環式誘導体 | |
| US20170100389A1 (en) | Tetrahydroprotoberbine compounds and uses thereof in the treatment of neurological, psychiatric and neurodegenerative diseases | |
| KR20100118113A (ko) | ７－(３-피리디닐)－１，７－디아자스피로［４．４］노난의제조 및 거울상이성질체 분리 및 라세미 화합물과 거울상이성질체의 신규한 염 형태 | |
| US10081600B2 (en) | 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof | |
| JP5384487B2 (ja) | 新規方法 | |
| EP3860996A1 (en) | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c) | |
| MXPA04008517A (es) | Compuestos terapeuticos. | |
| JP2024524629A (ja) | セロトニン５－ｈｔ２ａ、５－ｈｔ２ｂ、５－ｈｔ２ｃ受容体逆作動薬 | |
| AU2021329920A1 (en) | Serotonin receptor modulators | |
| BR112019010127B1 (pt) | Agentes psicotrópicos, seus usos, e composição farmacêutica | |
| BR122025015071A2 (pt) | Agentes psicotrópicos, seus usos, e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190308 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190308 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191126 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200218 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200602 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200626 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6726200 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |